4//SEC Filing
Meltz Mark A 4
Accession 0001415889-24-010424
CIK 0001797768other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:55 PM ET
Size
16.9 KB
Accession
0001415889-24-010424
Insider Transaction Report
Form 4
Meltz Mark A
COO General Counsel Treasurer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2024-04-03−384,508→ 0 totalExercise: $2.57Exp: 2030-04-02→ Common Stock (384,508 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−135,000→ 0 totalExercise: $10.03Exp: 2032-02-11→ Common Stock (135,000 underlying) - Disposition to Issuer
Common Stock
2024-04-03−27,578→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−121,503→ 0 totalExercise: $5.63Exp: 2030-08-18→ Common Stock (121,503 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−100,000→ 0 totalExercise: $35.38Exp: 2031-02-12→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2024-04-03−215,000→ 0 totalExercise: $6.78Exp: 2033-02-10→ Common Stock (215,000 underlying)
Footnotes (4)
- [F1]Includes 15,625 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
- [F2]Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. (the "Merger Agreement") in exchange for (i) $2.5879 in cash per share (the "Cash Amount"), plus (ii) one non-transferable contingent value right ("CVR") per share. Each RSU will receive the Cash Amount (without interest and less any applicable tax withholdings), plus one CVR.
- [F3]This option was cancelled pursuant to the Merger Agreement in exchange for (i) an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the per share exercise price of such in-the-money option by (y) the number of shares underlying such in-the-money option, plus (ii) one CVR for each share underlying such in-the-money option.
- [F4]This option was cancelled pursuant to the Merger Agreement in exchange for one CVR for each share underlying such out-of-the-money option. However, please note that such CVRs will provide payment only after the amounts payable under such CVRs exceed a threshold equal to the excess of the per share exercise price of such out-of-the-money option over the Cash Amount.
Documents
Issuer
Kinnate Biopharma Inc.
CIK 0001797768
Entity typeother
Related Parties
1- filerCIK 0001771329
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:55 PM ET
- Size
- 16.9 KB